Secura Bio® Media

News and Events

JUN 09, 2025, 7:00 AM ET

Secura Bio Announces First Patient Dosed in Phase 3 TERZO Study of COPIKTRA® (duvelisib) in Relapsed/Refractory Nodal T-follicular Helper Cell Lymphoma

View Press Release »

DEC 09, 2024, 7:00 AM ET

Secura Bio Presented New Data from its Phase 2 PRIMO Trial of Copiktra® (Duvelisib) in Relapsed or Refractory Peripheral T-cell Lymphoma and Announced Plans for its Phase 3 TERZO Trial at the 2024 American Society of Hematology Meeting

View Press Release »

DEC 09, 2024, 7:00 AM ET

New Combination Data of Secura Bio’s COPIKTRA® (duvelisib) Presented at the 2024 American Society of Hematology Meeting

View Press Release »

NOV 14, 2024, 4:00 PM ET

Secura Bio Appoints Dr. Patrick Vink as Chairman of the Board of Directors

View Press Release »

NOV 06, 2024, 7:00 AM ET

Secura Bio Announces Poster Presentation Highlighting New COPIKTRA® (duvelisib) Data for the Treatment of Patients With Peripheral T-Cell Lymphoma and Other Advanced Hematologic Malignancies at the 2024 American Society of Hematology Meeting

View Press Release »

OCT 15, 2024, 7:00 AM ET

Secura Bio Appoints Charles R. Romp as Its Chief Executive Officer

View Press Release »

DEC 07, 2023, 8:00 AM ET

Secura Bio Announces the Addition of Two New Board of Directors Members

View Press Release »

JAN 09, 2023, 9:00 AM ET

Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib for the Treatment of Patients with Peripheral T-cell Lymphoma

View Press Release »

FEB 09, 2022, 6:00 AM ET

Secura Bio® Announces Final Patient Enrolled in the COPIKTRA® (duvelisib) (PRIMO) Study in Relapsed and Refractory Peripheral T-cell Lymphoma

View Press Release »

DEC 14, 2021, 9:00 AM ET

Secura Bio® Announces the Presentation of New COPIKTRA® (duvelisib) Data for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas (PTCL)

View Press Release »

DEC 03, 2021, 4:30 PM ET

Secura Bio® Announces COPIKTRA® (duvelisib) Strategic Focus On T-cell Lymphoma And Voluntary U.S. Withdrawal Of The Relapsed Or Refractory Follicular Lymphoma Indication

View Press Release »

NOV 30, 2021, 4:45 PM ET

Secura Bio® Announces U.S. Withdrawal of FARYDAK® (panobinostat) NDA

View Press Release »

SEP 22, 2021, 9:00 AM ET

Secura Bio® Announces European Distribution Agreement for COPIKTRA® with Clinigen Healthcare Limited

View Press Release »

JUN 09, 2021, 9:00 AM ET

COPIKTRA® (duvelisib) Receives European Union Marketing Authorization for the Treatment of Relapsed or Refractory CLL and Refractory FL

View Press Release »

FEB 02, 2021, 9:00 AM ET

Secura Bio® Announces New Data Regarding the Combination of FARYDAK® (panobinostat) with Subcutaneous Bortezomib and Dexamethasone

View Press Release »

AUG 10, 2020, 9:23 AM ET

Secura Bio® Signs Agreement to Acquire Global Rights to Oncology Drug Copiktra®

View Press Release »

Mar 05, 2019, 10:07 AM ET

Secura Bio® Announces $145 Million Financing Led By Athyrium Capital Management

View Press Release »